“…4,5 According to the biopharmaceutical classification system (BCS), adopted by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as the basis for granting API biowaivers, 6,7 drugs included in class II present high permeability but low aqueous solubility, which impacts their oral bioavailability. [8][9][10] Many researchers have proven that by inducing structural modifications in the API solid forms, it is possible to increase the aqueous solubility and dissolution rate of drugs while maintaining their biological activity. [11][12][13][14] Among the referred structural modifications, cocrystal formation has emerged in the past two decades as an attractive way to modify the desired physicochemical properties since they allow crystalline structure modifications without making and/or breaking covalent bonds.…”